Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.33 |
| ▸ | RELA | Q04206 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916088 | 0.88 | CTSL (0.39) | GHSRCTSLAPLNRNFKB1NFKB2 | |
| SCHEMBL16407870 | 0.87 | GHSR (0.39) | GHSRCTSLAPLNRNFKB1NFKB2 | |
| SCHEMBL13307111 | 0.84 | CTSL (0.37) | GHSRCTSLAPLNRGAACA1 | |
| SCHEMBL17916089 | 0.84 | CTSL (0.37) | GHSRCTSLAPLNRGAACA1 | |
| SCHEMBL1953820 | 0.83 | GHSR (0.39) | GHSRCTSLAPLNRNFKB1NFKB2 | |
| SCHEMBL16409146 | 0.83 | GHSR (0.39) | GHSRCTSLAPLNRNFKB1NFKB2 | |
| SCHEMBL17916090 | 0.83 | CTSL (0.36) | GHSRCTSLAPLNRGAACA1 | |
| SCHEMBL19388522 | 0.82 | CTSL (0.36) | GHSRCTSLAPLNRGAACA1 | |
| SCHEMBL2745084 | 0.82 | GHSR (0.38) | GHSRCTSLAPLNRNFKB1NFKB2 | |
| SCHEMBL15114119 | 0.81 | CTSL (0.35) | GHSRCTSLAPLNRGAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | GHSR 4468/4885CTSL 1412/4885APLNR 4617/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | GHSR 4468/4885CTSL 1412/4885APLNR 4617/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | GHSR 4540/4885CTSL 1357/4885APLNR 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.